Log in

Relevant bibliographies by topics / Analisi costo-efficacia / Journal articles

To see the other types of publications on this topic, follow the link: Analisi costo-efficacia.

Journal articles on the topic 'Analisi costo-efficacia'

Author: Grafiati

Published: 9 March 2023

Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 32 journal articles for your research on the topic 'Analisi costo-efficacia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Matarese, Alessandro, Pier Giorgio Calò, Gabriele Materazzi, Viola Villardita, Maurizio Iacobone, Antonella Pino, Paolo Carcoforo, et al. "Analisi costo-efficacia del neuromonitoraggio nella chirurgia della tiroide." L'Endocrinologo 23, no. 3 (June 2022): 290–96. http://dx.doi.org/10.1007/s40619-022-01085-6.

Full text

Abstract:

SommarioVi sono prove sempre più rilevanti circa l’importanza di una più dettagliata valutazione dei costi delle nuove tecnologie usate in chirurgia. L’impatto innovativo della tecnologia ha il potenziale per ottenere miglioramenti clinici rivoluzionari. Tuttavia, esistono informazioni limitate sul tema costo-efficacia delle nuove strategie chirurgiche usate in chirurgia tiroidea. In questo studio descriviamo le recenti evidenze relative ai metodi di valutazione costo-efficacia delle strutture e delle funzioni per il neuromonitoraggio intraoperatorio (IONM) in chirurgia tiroidea. I nostri risultati suggeriscono che il modello di economia sanitaria, nell’elaborazione della struttura degli studi costo-efficacia relativi al neuromonitoraggio intraoperatorio, si è dimostrata realizzabile come metodo per migliorare l’efficacia della ricerca.

APA, Harvard, Vancouver, ISO, and other styles

2

Iannazzo, Sergio, Lorenzo Pradelli, Roberto W. Dal Negro, and Mario Eandi. "Analisi di costo efficacia nella terapia della BPCO." Farmeconomia. Health economics and therapeutic pathways 6, no. 4 (December 15, 2005): 277–87. http://dx.doi.org/10.7175/fe.v6i4.843.

Full text

Abstract:

Current practice guidelines for the treatment of COPD recommend the use of combined inhaled corticosteroids and long-acting bronchodilators in severe and very severe patients (GOLD stages III and IV). OBJECTIVES: To analyze the economical and clinical impact of this recommendation, the affordability of its widespread application, as well as the relative pharmacoeconomical performance of the available options for severe and very severe COPD in Italy. METHODS: Published data on the Italian COPD population were fitted in a disease progression model based on a Markov chain representing severity stages and death. Alternative therapeutic options (salmeterol/ fluticasone - SF, formoterol/budesonide - FB, salmeterol alone - S, fluticasone alone - F and control - C) were represented as competing arms in a decision tree. Efficacy data from international trials were expressed in terms of risk reduction. Clinical parameters used were number of exacerbations and symptom-free days. Direct and indirect costs were considered and valued according to present prices and tarifs. The analyses were conducted from National Health System, societal and patient perspectives with time horizons of 1,5, and 10 years, and lifelong. RESULTS: The yearly total direct costs of treating COPD patients in Italy is estimated in approximately 7 billion Euro, with a mean cost/patient/year around 2,400 Euro. Mean survival of the cohort is 11,5 years. The C and F strategies are dominated (i.e. are associated with worse outcomes and higher costs) by all alternatives. S/F and F/B are the most effective strategies, with a slight clinical superiority of the latter, but are also marginally more expensive than S. Incremental cost/effectiveness of S/F vs. S is 679,55 Euro/avoided exacerbation and 3,31Euro/gained symptom-free day. CONCLUSIONS: The recommended use of combined inhaled corticosteroids and long-acting bronchodilators for severe and very severe COPD patients, as compared with current practice, has the potential of improving clinical outcomes without increasing health care costs.

APA, Harvard, Vancouver, ISO, and other styles

3

Berto, Patrizia, M. Breccia, and R. Latagliata. "Analisi costo-efficacia di dasatinib nella prospettiva del SSN italiano." Giornale Italiano di Health Technology Assessment 3, no. 1 (July 2010): 13–29. http://dx.doi.org/10.1007/bf03320729.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Bondonio, Piervincenzo. "Le analisi costo della malattia e costo efficacia in farmacoeconomia. Ambiti di applicabilità, problemi, prospettive." Farmeconomia. Health economics and therapeutic pathways 1, no. 1 (March 15, 2000): 9–18. http://dx.doi.org/10.7175/fe.v1i1.707.

Full text

Abstract:

Aim of the paper is to compare and evaluate some of the main features of two different tecniques of economic analyses: cost of illness e and cost-effectiveness. The former is not so widely used in pharmacoeconomics, while the latter is dominant. Although their theory has recently much progressed, their practice is still hindered by some unresolved questions, to which the paper also addressess.

APA, Harvard, Vancouver, ISO, and other styles

5

Eandi, Mario, Nicola Giotta, and Gaia Santagostino Barbone. "Analisi costo/efficacia di sevelamer nel trattamento dell’iperfosforemia del paziente in dialisi." Farmeconomia. Health economics and therapeutic pathways 5, no. 4 (December 15, 2004): 201–18. http://dx.doi.org/10.7175/fe.v5i4.809.

Full text

Abstract:

Dialysis-associated hyperphosphatemia has been treated with chelating calcium salts, in particular with calcium carbonate. A new option for the management of this problem is represented by sevelamer, a chelating agent which contains no calcium and no metals. Sevelamer and calcium carbonate are more or less equally effective and tolerated. The prolonged use of sevelamer instead of calcium carbonate, nevertheless, reduces calcemia and C-reactive protein levels, with a consequent reduction in myocardial infarction, angina pectoris and other peripheral vasculopathies. The limit to the wide-spread use of sevelamer is in its very high acquisition cost, as compared to the alternative. In this article, a semi-markovian pharmacoeconomical model for the comparison of clinical and economical outcomes of sevelamer and calcium carbonate is presented. The analysis is conducted in the perspective of the Italian health system (SSN). Clinical data are derived from published studies and integrated with expert panel estimates, cost data are relative to the Italian setting. The incremental cost-effectiveness analysis indicated that sevelamer is more costly, but also more costeffective: a one month gain in survival costs the SSN additional 2710 Euro, a value inferior to the conventionally accepted willingness-to-pay of industrialised countries. The majority of this excess cost is derived from the gain in survival, and consequent increase in dialysis costs. Thus, the choice of using sevelamer instead of calcium carbonate is even more justified from an ethical point of view. Sensibility analyses confirmed the robustness of the basic scenario results.

APA, Harvard, Vancouver, ISO, and other styles

6

Eandi, Mario, Elisa Berno, and Lorenzo Pradelli. "Analisi costo/efficacia della doxofillina vs. teofillina nella terapia dell’asma cronica reversibile dell’adulto." Farmeconomia. Health economics and therapeutic pathways 3, no. 2 (June 15, 2002): 103–17. http://dx.doi.org/10.7175/fe.v3i2.748.

Full text

Abstract:

Doxofylline is a methyl-xanthine with bronchodilator activity which clinical efficacy in the treatment of asthma and COPD is equivalent to theophylline. Clinical trials prooved that while doxofylline is as effective as theophylline in the treatment of asthma, it is associated with lesser side effects. For our pharmacoeconomical evaluation, we employed the data of an international multi-centric study that compared the efficacy and tolerability of 12 weeks of treatment with either theophylline 250 mg tid, or doxofylline 400 mg tid, or placebo. The efficacy was evaluated with pulmonary function tests and by recording the number of asthma attacks and beta-2 agonist puffs: doxofylline 1200 mg/day and theophylline 750 mg/day resulted equally effective, but the former resulted better tolerated, as the adverse effects were lesser in number and severity. We performed a cost/effectiveness analysis in order to compare the two treatments, considering the perspective of the Italian health system (SSN) and of the Italian society. For the purposes of this analysis, the efficacy indices we considered were two: one simple, consisting in the number of avoided asthma attacks (AAA), and a more complex one, i.e. UATD (Utility Adjusted Therapy Days). For the construction of this index, we extracted the survival curve of the patients remaining in therapy; this curve showed that the cumulative number of therapy days is significantly greater in the doxofylline group, although the percentage of dropouts is similar at the end of the three months: this is due to the fact that the drop-outs in the theophylline group occur earlier after treatment start. The number of therapy days was then weighed for an utility index inversely proportional to the main daily number of avoided asthma attacks, thus obtaining the UATDs. The results of the cost/effectiveness analyses showed that doxofylline dominates theophylline treatment in asthma, as it is less expensive and more effective (in terms of AAAs and UATDs) for both considered decision-makers, i.e. Italian SSN and society. The consistency of these results was further confirmed by oneway sensitivity analyses.

APA, Harvard, Vancouver, ISO, and other styles

7

Franzosi, Maria Grazia, A. P. Maggioni, E. Santoro, G. Tognoni, and E. Cavalieri. "Analisi costo-efficacia dell’impiego precoce di lisinopril nei pazienti con infarto miocardico acuto." PharmacoEconomics Italian Research Articles 2, no. 1 (September 2000): 43–52. http://dx.doi.org/10.1007/bf03320573.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Russo, Pierluigi, E. Attanasio, O. Leri, F. Fiocca, and G. I. Togna. "Analisi costo-efficacia di due combinazioni sequenziali di trattamenti di eradicazione dell’Helicobacter pylori." PharmacoEconomics Italian Research Articles 3, no. 1 (March 2001): 15–25. http://dx.doi.org/10.1007/bf03320576.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Standaert, B., A. Marocco, B. Assael, G. Gabutti, A. Guarino, P. L. Lopalco, Federico Marchetti, et al. "Analisi di costo-efficacia della vaccinazione universale in Italia con il vaccino Rix4414 contro i rotavirus." PharmacoEconomics Italian Research Articles 10, no. 1 (March 2008): 23–35. http://dx.doi.org/10.1007/bf03320638.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Berto, P., A. Morsanutto, S. Lopatriello, M. Martelli, G. Muti, G. Santini, and U. Vitolo. "Analisi costo-efficacia di rituximab + CHOP versus CHOP in soggetti affetti da linfoma non-Hodgkin aggressivo." PharmacoEconomics Italian Research Articles 6, no. 3 (November 2004): 151–60. http://dx.doi.org/10.1007/bf03320633.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Baio, Gianluca, and Pierluigi Russo. "Un modello di analisi del valore dell’informazione per la valutazione di costo-efficacia nell’ambito del processo regolatorio." PharmacoEconomics Italian Research Articles 12, no. 1 (March 2010): 5–16. http://dx.doi.org/10.1007/bf03320526.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lazzaro, C., P. Ruffo, and M. Gozzo. "Analisi costo-efficacia dell’associazione budesonide/formoterolo come terapia di mantenimento e “al bisogno” nella gestione dell’asma. Valutazione italiana." PharmacoEconomics Italian Research Articles 11, no. 1 (March 2009): 39–53. http://dx.doi.org/10.1007/bf03320656.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Olivares, Josè M., Alfonso Rodriguez-Martinez, Josè A. Buron, David Alonso-Escolano, and Alexander Rodriguez-Morales. "Analisi costo-efficacia dello switch da un trattamento antipsicotico a risperidone iniettabile a rilascio prolungato in pazienti con schizofrenia." Giornale Italiano di Health Technology Assessment 1, no. 1 (January 2008): 39–48. http://dx.doi.org/10.1007/bf03320712.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Oliveri, C., F. Polcaro, and R. Ravasio. "Analisi economica di exenatide rispetto a liraglutide nei pazienti con diabete di tipo 2: costo-efficacia e budget impact." Giornale Italiano di Health Technology Assessment 3, no. 2 (September 2010): 73–79. http://dx.doi.org/10.1007/bf03320735.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Lucioni, Carlo, S. Mazzi, and K. Neeser. "Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia." PharmacoEconomics Italian Research Articles 6, no. 2 (July 2004): 81–93. http://dx.doi.org/10.1007/bf03320626.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Ravasio, Roberto, N. Giotta, A. Marino, M. Colombo, F. Caligaris, G. Cesano, A. Grill, D. Sassone, and E. Biamino. "Analisi costo-efficacia di cinacalcet più terapia standard versus terapia standard nel trattamento dei pazienti in dialisi con iperparatiroidismo secondario." PharmacoEconomics Italian Research Articles 10, no. 1 (March 2008): 13–22. http://dx.doi.org/10.1007/bf03320637.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Ravasio, Roberto. "Analisi di costo efficacia di trastuzumab nel trattamento adiuvante del carcinoma mammario precoce HER-2 positivo: l’esperienza della Regione Toscana." Giornale Italiano di Health Technology Assessment 2, no. 3 (September 2009): 89–98. http://dx.doi.org/10.1007/bf03320724.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Marchetti, Monia, and Giorgio Lorenzo Colombo. "Considerazioni cliniche ed economiche nel trattamento del cancro della prostata: analisi costo-efficacia di bicalutamide vs flutamide in combinazione con LHRH." Farmeconomia. Health economics and therapeutic pathways 4, no. 3 (September 15, 2003): 153–68. http://dx.doi.org/10.7175/fe.v4i3.776.

Full text

Abstract:

Prostate carcinoma (PC) is the most common malign neoplasm found in men over 65 years of age. In Italy, the incidence of this cancer is around 60/100,000/year, corresponding to about 11,000 new cases each year. Patients with PC consume health resources for a cost that is 10-24% higher than that of similar populations without PC. It is estimated that in Italy, each year, there are 19,000 hospitalizations for prostate cancer in patients over 65, a figure that represents 4% of the total hospitalizations for oncological diseases. We conducted a marginal cost/effectiveness analysis of bicalutamide vs. flutamide, both administered in combination with LHRH, in patients with advanced (metastatic) PC, on the basis of a randomized trial comparing 4 strategies of total androgenic blockade (TAB). The analysis was conducted in the perspective of the SSN (National health system). The comparison revealed that drug acquisition costs are not the only determinants of the economical differences between the two therapeutical strategies. Furthermore, we demonstrated that prolonged survival of the patients does not increase the consumption of health resources, since the chronological shift of the terminal phase reduces the value of the resources dedicated to it. When conducing the cost/effectiveness analysis, the survival advantage associated to bicalutamide has been adjusted to balance the low quality of life of PC patients. The pharmacoeconomical benefit of bicalutamide resulted of 12,150 Euro/QALY, while the cost per year of life saved resulted inferior, ranging from 8.327 to 11.440 Euro. This cost/QALY value is nevertheless lower than that associated to several therapeutical strategies that are commonly accepted in developed countries (domiciliar hemodialysis, heart transplantation, breast cancer screening, etc.). Considering that 12.150 Euro/QALY is the highest estimate of the relative cost/effectiveness of bicalutamide, it appears that the combination bicalutamide + LHRH represents an economically acceptable alternative to flutamide + LHRH in advanced PC patients.

APA, Harvard, Vancouver, ISO, and other styles

19

Eandi, Mario. "Analisi Costo-Efficacia di Amfotericina B Liposomiale (L-AmB) versus Amfotericina B Complesso Lipidico (ABLC) nel trattamento empirico della neutropenia febbrile." Farmeconomia. Health economics and therapeutic pathways 6, no. 4 (December 15, 2005): 333–47. http://dx.doi.org/10.7175/fe.v6i4.851.

Full text

Abstract:

Current international guidelines for the management of immuno-compromised patients with febrile neutropenia recommend a systemic antimicrobial therapy if fever hasn’t receded after three days of antibiotic treatment. Amphotericin B remains the gold standard because of its broad spectrum fungicidal action and minimal resistance development risk. Nonetheless, therapeutic use of the standard formulation, Amphotericin B deoxycholate, is limited by its toxicity, especially on the kidneys. To counteract this, amphotericin B has been encapsulated in liposomes, a process which reduces its toxicity and allows higher doses to be given. Three lipid formulations have been developed and are now available in most countries: amB colloidal dispersion (ABCD), amB lipid complex (ABLC), and liposomal amB (L-AmB). These lipid formulations differ in pharmacodynamics and pharmacokinetics, and can’t therefore be considered interchangeable. Besides, they are more expensive than Amphotericin B deoxycholate. Aim of the study is to perform a cost/effectiveness analysis (CEA) comparing L-AmB (3mg/kg/die or 5mg/kg/ die) and ABLC (5mg/kg/die) as first-line antimicrobial empirical treatments in immuno-compromised patients with febrile neutropenia resistant to broad spectrum antibiotics. Secondly, we present a cost-minimization analysis (CMA) of the considered alternatives, assuming the same efficacy for all treatments. At the end we value the principal cost items from the point of view of the Italian Health Service, with a particular focus on the economic burden caused by adverse reactions.

APA, Harvard, Vancouver, ISO, and other styles

20

Rebesco, Barbara, Elena Cantagalli, and Maria Elvira Amalfitano. "Analisi costo-efficacia di due schemi adiuvanti per il trattamento del carcinoma del colon-retto: lettura dei dati dello studio mosaic." Tumori Journal 91, no. 6 (November 2005): 1–10. http://dx.doi.org/10.1177/030089160509100628.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Ravasio, R., L. Sanfilippo, G. De Paoli, C. Cerra, P. Fratino, and M. Della Giovanna. "Analisi di costo-efficacia dello switch da un antipsicotico orale a risperidone a rilascio prolungato nel trattamento dei pazienti affetti da schizofrenia." Giornale Italiano di Health Technology Assessment 2, no. 1 (March 2009): 1–8. http://dx.doi.org/10.1007/bf03320713.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Castorina, Sebastiano Maurizio. "Rettifica al lavoro: considerazione cliniche ed economiche nel trattamento del cancro della prostata: analisi costo/efficacia di bicalutamide vs. flutamide in combinazione con LHRH." Farmeconomia. Health economics and therapeutic pathways 5, no. 1 (March 15, 2004): 31–32. http://dx.doi.org/10.7175/fe.v5i1.787.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Ravasio, R. "Analisi di costo-efficacia di exenatide versus insulina glargine nel trattamento dei pazienti diabetici di tipo 2 in fallimento secondario al doppio ipoglicemizzante orale." Giornale Italiano di Health Technology Assessment 1, no. 1 (January 2008): 21–30. http://dx.doi.org/10.1007/bf03320710.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Merli, F., Roberto Ravasio, I. Alvarez De Cielis, and F. Polcaro. "Analisi di costo-efficacia di rituximab più CHOP versus ProMACE-CytaBOM nel trattamento del linfoma diffuso a grandi cellule B: l’esperienza di Reggio Emilia." Giornale Italiano di Health Technology Assessment 2, no. 2 (June 2009): 55–64. http://dx.doi.org/10.1007/bf03320719.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Ravasio, Roberto. "Analisi di costo efficacia di emtricitabina/tenofovir disoproxil più efavirenz rispetto ad altri regimi antiretrovirali nel trattamento di prima linea di pazienti affetti da HIV." Giornale Italiano di Health Technology Assessment 3, no. 1 (July 2010): 1–11. http://dx.doi.org/10.1007/bf03320728.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Ravasio, Roberto. "Analisi di costo-efficacia di prasugrel rispetto a clopidogrel nel trattamento di pazienti con sindrome coronarica acuta e intervento di angioplastica per via percutanea programmato." Giornale Italiano di Health Technology Assessment 3, no. 2 (September 2010): 55–63. http://dx.doi.org/10.1007/bf03320733.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ravasio, Roberto, and L. Guidi. "Analisi di costo-efficacia di pemetrexed più cisplatino versus gemcitabina più cisplatino nel trattamento di prima linea in pazienti con NSCLC non squamoso in stadio avanzato." Giornale Italiano di Health Technology Assessment 2, no. 2 (June 2009): 73–80. http://dx.doi.org/10.1007/bf03320721.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Ravasio, R., L. Guidi, D. Valle, K. Taipale, and Y. Asukai. "Analisi di costo-efficacia nel trattamento di prima linea con i regimi chemioterapici pemetrexed più cisplatino, gemcitabina più cisplatino e bevacizumab più gemcitabina più cisplatino in pazienti con NSCLC localmente avanzato o metastatizzato in Italia." Giornale Italiano di Health Technology Assessment 2, no. 3 (September 2009): 99–109. http://dx.doi.org/10.1007/bf03320725.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Macêdo, Karen Vanderlei. "Diritto alla salute: La legalizzazione della concessione di medicinali ad alto costo." Revista Científica Multidisciplinar Núcleo do Conhecimento, December 10, 2020, 05–16. http://dx.doi.org/10.32749/nucleodoconhecimento.com.br/legge/diritto-alla-salute.

Full text

Abstract:

Oggetto di analisi di questo articolo è l’intreccio tra il diritto alla salute in Brasile e l’attivazione della Corte Suprema Federale (STF) come garanzia di efficacia pratica, la legalizzazione della politica, in particolare, la concessione di farmaci ad alto costo. In vista del diritto alla salute in Brasile si scontrano due Principi, la riserva del possibile e il minimo esistenziale, che richiede, secondo Barroso (2009), una considerazione da parte dell’interprete della legge sulla ragionevolezza dei casi concreti. Al fine di verificare, in tema di diritto alla salute, abbiamo analizzato alcune Sentenze STF in materia, che appaiono sul suo sito web. Notiamo che c’è una preponderanza della riserva del possibile nelle decisioni della STF a scapito del minimo esistenziale.

APA, Harvard, Vancouver, ISO, and other styles

30

Ravasio, Roberto, M. P. Pedone, and M. Ratti. "Analisi di costo efficacia dei nuovi anticoagulanti orali nella prevenzione dell’ictus in pazienti con fibrillazione atriale non valvolare in Italia." PharmacoEconomics Italian Research Articles 16, no. 2-3 (August 7, 2014). http://dx.doi.org/10.1007/s40276-014-0022-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Ravasio, Roberto, M. P. Pedone, and M. Ratti. "Erratum a: Analisi di costo efficacia dei nuovi anticoagulanti orali nella prevenzione dell’ictus in pazienti con fibrillazione atriale non valvolare in Italia." PharmacoEconomics Italian Research Articles 17, no. 1 (December 10, 2014). http://dx.doi.org/10.1007/s40276-014-0024-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

"Costo-efficacia dell’aggiunta di empagliﬂozin alla terapia di pazienti diabetici con malattia renale negli Stati Uniti: analisi dei risultati dello studio EMPA-REG." il Diabete 33, no. 4 (2021). http://dx.doi.org/10.30682/ildia2104e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!